Hepatic fibrosis is an important pathological change during NAFLD progression, and our data showed that miR-137-3p agomir significantly prevented HFD-induced hepatic fibrosis in mice, as confirmed by the decreased hepatic hydroxyproline content and mRNA levels of fibrotic markers, including Col1α1, Col3α1, CTGF, and TGF-β1 (Figures 1(n) and 1(o)). This evidence concerns the gene CCN2 and metabolic dysfunction-associated steatotic liver disease.